Detrus^® (Tablets) Instructions for Use

Marketing Authorization Holder

Avva Rus, JSC (Russia)

ATC Code

C05CA53 (Diosmin in combination with other drugs)

Active Substances

Diosmin (Rec.INN)

Hesperidin (Grouping name)

Dosage Forms

	Detrus^®	Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 60 or 90 pcs.
		Film-coated tablets, 100 mg+900 mg: 30 or 60 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from yellow with a brownish tint to light brown in color, biconvex, capsule-shaped; on the cross-section, the core is from grayish-yellow to brownish-gray in color; inclusions are allowed.

	1 tab.
Hesperidin	50 mg
Diosmin	450 mg

Excipients: crospovidone XL-10 – 45.5 mg, sodium stearyl fumarate – 13 mg, talc – 6.5 mg, microcrystalline cellulose 102 – 650 mg.

Coating mixture “Opadry^® 20A220058 yellow” [hypromellose 2910 – 33.75%, hypromellose – 33.75%, talc – 20%, titanium dioxide – 11.1%, iron oxide yellow dye – 1.4%].

10 pcs. – blister packs (2) – cardboard boxes.
10 pcs. – blister packs (3) – cardboard boxes.
10 pcs. – blister packs (4) – cardboard boxes.
10 pcs. – blister packs (6) – cardboard boxes.
15 pcs. – blister packs (2) – cardboard boxes.
15 pcs. – blister packs (3) – cardboard boxes.
15 pcs. – blister packs (4) – cardboard boxes.
15 pcs. – blister packs (6) – cardboard boxes.

Film-coated tablets from yellow with a brownish tint to light brown in color, biconvex, capsule-shaped, with a score; on the cross-section, the core is from grayish-yellow to brownish-gray in color; inclusions are allowed.

	1 tab.
Hesperidin	100 mg
Diosmin	900 mg

Excipients: crospovidone XL-10 – 91 mg, sodium stearyl fumarate – 26 mg, talc – 13 mg, microcrystalline cellulose 102 – 1300 mg.

Coating mixture “Opadry^® 20A220058 yellow” [hypromellose 2910 – 33.75%, hypromellose – 33.75%, talc – 20%, titanium dioxide – 11.1%, iron oxide yellow dye – 1.4%].

10 pcs. – blister packs (3) – cardboard boxes.
10 pcs. – blister packs (6) – cardboard boxes.

Clinical-Pharmacological Group

Venotonic drug

Pharmacotherapeutic Group

Angioprotectors; capillary stabilizing agents; bioflavonoids

Pharmacological Action

A combined agent with angioprotective and venotonic action, containing bioflavonoids.

It reduces venous distensibility, increases venous tone, and reduces venous stasis; reduces capillary permeability, fragility, and increases their resistance; improves microcirculation and lymphatic drainage.

With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of organic and functional nature.

Indications

Symptomatic therapy of venous insufficiency of the lower extremities: sensation of heaviness and pain in the legs.

Symptomatic therapy of acute hemorrhoids.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
I87.2	Venous insufficiency (chronic) (peripheral)
K64	Hemorrhoids and perianal venous thrombosis

ICD-11 code	Indication
BD74.Z	Chronic venous insufficiency of lower extremities, unspecified
DB6Z	Hemorrhoids or perianal venous diseases, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take orally.

For venolymphatic insufficiency, the daily dose is 900 mg of diosmin + 100 mg of hesperidin.

The frequency of administration is 2 times/day (at midday and in the evening during meals).

For acute hemorrhoids, during the first 4 days the daily dose is 2.7 g of diosmin + 300 mg of hesperidin (in 2 doses in the morning and evening), during the following 3 days the daily dose is 1.8 g of diosmin + 200 mg of hesperidin (in 2 doses in the morning and evening).

Adverse Reactions

From the digestive system: often – diarrhea, nausea, vomiting, dyspepsia; infrequently – colitis.

From the CNS rarely – dizziness, headache, general malaise.

From the skin: rarely – rash, itching, urticaria; unspecified frequency – isolated edema of the face, lips, eyelids; in exceptional cases – angioedema.

Contraindications

Lactation period (breastfeeding), hypersensitivity to diosmin and hesperidin.

Use in Pregnancy and Lactation

To date, there have been no reports of any adverse effects from the use of this combination in pregnant women.

Experimental studies have not observed teratogenic effects of the Diosmin+Hesperidin combination.

Contraindicated for use during lactation (breastfeeding), as it is unknown whether Diosmin and Hesperidin are excreted in breast milk.

Special Precautions

In case of hemorrhoid exacerbation, the use of this combination does not replace specific treatment for other anal disorders.

The duration of treatment should not exceed the recommended periods.

If symptoms do not disappear after short-term therapy, a proctological examination should be performed and the ongoing therapy should be reviewed.

For venous circulation disorders, the maximum treatment effect is achieved by combining it with a healthy, well-balanced lifestyle, which preferably includes avoiding prolonged sun exposure, prolonged standing, as well as reducing excess body weight, taking walks, and in some cases – wearing special stockings that improve blood circulation.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer